Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
22.47
Price to sales ratio
1.85

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2576
AMPH
Amphastar Pharmaceuticals, Inc. - Common Stock
19.29 USD+3.04%-3.84%-3.07%-20.88%850.55 M USD
2602
ESPR
Esperion Therapeutics, Inc. - Common Stock
3.18 USD0.00%+0.63%+0.63%+169.49%818.63 M USD
2896
TLRY
Tilray Brands, Inc. - Common Stock
4.46 USD+0.90%+0.45%-12.20%+565.67%519.81 M USD
2911
AQST
Aquestive Therapeutics, Inc. - Common Stock
4.06 USD-1.46%-5.80%-3.56%+0.50%509.33 M USD

Frequently asked questions about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

What is the Ironwood Pharmaceuticals, Inc. - Class A Common Stock stock price today?

The current price of Ironwood Pharmaceuticals, Inc. - Class A Common Stock (IRWD) is 4.21. Over the past 24 hours, the stock has changed by -5.82%. Follow the IRWD chart for real-time price dynamics.

What is the stock ticker of Ironwood Pharmaceuticals, Inc. - Class A Common Stock?

Ironwood Pharmaceuticals, Inc. - Class A Common Stock trades under the ticker IRWD. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Ironwood Pharmaceuticals, Inc. - Class A Common Stock stock going up?

IRWD has changed by -6.03% over the last week, +11.67% over the last month, and +468.92% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Ironwood Pharmaceuticals, Inc. - Class A Common Stock net income for the last quarter?

Ironwood Pharmaceuticals, Inc. - Class A Common Stock reported net income of 40.77 M for the last quarter. The previous quarter showed -2.28 M, which means net income changed by +1891.43%.

How many employees does Ironwood Pharmaceuticals, Inc. - Class A Common Stock have?

As of the latest available data, Ironwood Pharmaceuticals, Inc. - Class A Common Stock has 100 employees. Workforce size can provide additional context about the company's scale and operations.

What is Ironwood Pharmaceuticals, Inc. - Class A Common Stock EBITDA?

Ironwood Pharmaceuticals, Inc. - Class A Common Stock EBITDA is 73.02 M, and its EBITDA margin is 68.56%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Ironwood Pharmaceuticals, Inc. - Class A Common Stock stock?

You can buy Ironwood Pharmaceuticals, Inc. - Class A Common Stock (IRWD) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Ironwood Pharmaceuticals, Inc. - Class A Common Stock stock?

Investing in Ironwood Pharmaceuticals, Inc. - Class A Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the IRWD chart and related analysis on metatrader.com as part of your research.

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide.

News